| Literature DB >> 24745029 |
Yoshihiro Okuda1, Shugo Mizuno1, Taizou Shiraishi2, Yasuhiro Murata1, Akihiro Tanemura1, Yoshinori Azumi1, Naohisa Kuriyama1, Masashi Kishiwada1, Masanobu Usui1, Hiroyuki Sakurai1, Masami Tabata1, Tomomi Yamada3, Shuji Isaji1.
Abstract
We evaluated clinicopathological factors affecting survival and recurrence after initial hepatectomy in non-B non-C (NBNC) hepatocellular carcinoma (HCC) patients with comparison to hepatitis B or C virus, paying attention to relationship between alcohol consumption and histopathological findings. The medical records on the 201HCC patients who underwent initial hepatectomy between January 2000 and April 2013 were retrospectively reviewed. NBNC patients had higher prevalence of hypertension (47.4%), diabetes mellitus (35.5%), alcohol consumption (>20 g/day) (61.8%), and preserved liver function than hepatitis B or C patients. The 5-year survival rate of NBNC patients (74.1%) was significantly better than hepatitis B (49.1%) or C (65.0%) patients (NBNC versus B, P = 0.031). Among the NBNC patients, there was no relationship between alcohol consumption and clinicopathological findings including nonalcoholic fatty liver disease activity score (NAS). However, the 5-year OS and RFS rates in the alcohol-unrelated NBNC patients tend to be better than in the alcohol-related. By multivariate analysis, independent factors for OS in NBNC patients were Child-Pugh B/C, intrahepatic metastasis (im), and extrahepatic recurrence. NBNC patients, who were highly associated with lifestyle-related disease and preserved liver function, had significantly better prognosis compared to hepatitis B/C patients; however, there was no association between alcohol consumption and histopathological findings.Entities:
Mesh:
Year: 2014 PMID: 24745029 PMCID: PMC3972956 DOI: 10.1155/2014/975380
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Lifestyle-related and preoperative clinical factors.
| B ( | C ( | NBNC ( |
| |
|---|---|---|---|---|
| Age (years) | 61.1 ± 13.6 | 67.2 ± 6.6 | 71.0 ± 9.2 |
|
| Gender (male/female) | 23/9 | 70/23 | 67/9 | 0.058 |
| Obesity | 3 (9.4%) | 17 (18.3%) | 15 (19.7%) | 0.412 |
| Hypertension | 6 (18.8%) | 26 (28.0%) | 36 (47.4%) |
|
| DM | 5 (12.0%) | 20 (21.5%) | 27 (35.5%) |
|
| Cigarette smoking | 19 (59.4%) | 55 (59.1%) | 47 (61.8%) | 0.933 |
| Ethanol ≧ 20 g | 5 (15.6%) | 38 (40.9%) | 46 (60.5%) |
|
| Albumin (g/dL) | 3.6 (2.3–4.5) | 3.7 (2.8–4.5) | 3.8 (2.5–5.0) | 0.104 |
| Total bilirubin (mg/dL) | 0.5 (0.2–1.2) | 0.5 (0.2–1.4) | 0.5 (0.2–1.3) | 0.873 |
| Platelet count (×104/mm3) | 14.0 (4.3–48.9) | 16.1 (4.4–51.0) | 19.2 (6.7–51.6) |
|
| NLR | 2.21 (0.79–4.90) | 1.92 (0.52–14.16) | 2.16 (0.67–12.80) | 0.271 |
| PT (%) | 82.9 (64.3–105.0) | 90.0 (63.4–122.7) | 95.4 (54.8–131.4) |
|
| ICG R15 (%) | 12.7 (4.4–19.7) | 14.0 (2.8–42.3) | 10.9 (1.6–36.7) |
|
| Child-Pugh B/C | 2 (6.3%) | 5 (5.4%) | 6 (7.9%) | 0.802 |
| AFP (ng/mL) | 110.0 (1–605100) | 14.0 (2–11675) | 6.0 (1–48157) |
|
| DCP (mAU/mL) | 267.0 (10–174400) | 148.0 (10–23950) | 87.0 (11–85330) | 0.653 |
| Multiple tumors | 10 (31.3%) | 25 (26.9%) | 22 (28.9%) | 0.885 |
| Tumor size (cm) | 5.2 (1.0–20.0) | 3.0 (0.7–11.0) | 4.5 (1.0–17.0) |
|
| ≧10 cm | 7 (21.9%) | 2 (2.2%) | 14 (18.4%) |
|
| BCLC stage B/C | 8 (25.0%) | 16 (17.2%) | 18 (23.7%) | 0.484 |
| Beyond Milan criteria | 15 (46.9%) | 26 (28.0%) | 38 (50.0%) |
|
| Preoperative TACE | 17 (53.1%) | 60 (64.5%) | 42 (55.3%) | 0.356 |
DM: diabetes mellitus; NLR: neutrophil-to-lymphocyte ratio; PT: prothrombin time; ICG R15: indocyanine green retention rate at 15 minutes; AFP: serum α-fetoprotein; DCP: des-r-carboxyprothrombin; BCLC: Barcelona Clinic Liver Cancer; TACE: transcatheter arterial chemoembolization.
Intraoperative, pathological and postoperative factors.
| B ( | C ( | NBNC ( |
| |
|---|---|---|---|---|
| ≧2 sentionectomy | 13 (40.6%) | 17 (18.3%) | 32 (42.1%) |
|
| Operative Time (min.) | 352 (177–658) | 333 (135–750) | 367 (173–983) | 0.142 |
| Blood loss (g) | 1137 (38–8488) | 1182 (5–8307) | 1226 (200–36000) | 0.590 |
| Curability R0 | 27 (84.4%) | 88 (94.6%) | 70 (92.1%) | 0.181 |
| Simple nodular type | 12 (37.5%) | 54 (58.1%) | 30 (39.5%) |
|
| Poorly differentiated | 6 (18.8%) | 14 (15.1%) | 6 (7.9%) | 0.218 |
| fc(+) | 24 (75.0%) | 63 (67.7%) | 44 (57.9%) | 0.182 |
| vp(+) | 17 (53.1%) | 24 (25.8%) | 28 (36.8%) |
|
| vv(+) | 5 (15.6%) | 4 (4.3%) | 7 (9.2%) | 0.109 |
| im(+) | 6 (18.8%) | 7 (7.5%) | 7 (9.2%) | 0.181 |
| Non-cancerous liver NL | 1 (3.1%) | 1 (1.1%) | 23 (30.3%) |
|
| CH | 17 (53.1%) | 44 (47.3%) | 29 (38.2%) | 0.288 |
| LC | 14 (43.8%) | 48 (51.6%) | 23 (30.3%) |
|
| Clavien-Dindo ≧ III | 5 (15.6%) | 19 (20.4%) | 12 (15.8%) | 0.688 |
| PHLF B/C | 7 (21.9%) | 28 (30.1%) | 18 (23.7%) | 0.526 |
| 90-day mortality | 4 (12.5%) | 6 (6.5%) | 6 (7.9%) | 0.552 |
| Intrahepatic recurrence | 13 (40.6%) | 47 (50.5%) | 25 (32.9%) | 0.068 |
| Extrahepatic recurrence | 7 (21.9%) | 8 (8.6%) | 7 (9.2%) | 0.096 |
fc: formation of capsule; vp: microscopic portal vein invasion; vv: microscopic hepatic vein invasion; im: intrahepatic metastasis; NL: normal liver; CH: chronic hepatitis; LC: liver cirrhosis; PHLF: posthepatectomy liver failure.
Figure 1Comparisons of overall survival and recurrence-free survival rates after hepatectomy between patients in groups B, C, and NBNC. (a) Overall survival. The survival rate of NBNC patients (unbroken thick line) was significantly better than that of B patients (unbroken line, P = 0.031). (b) Recurrence-free survival. There were no significant differences in survival rates of three groups.
Lifestyle-related and preoperative clinical factors in Group NBNC according to alcohol consumption.
| NALP ( | ALP ( |
| |
|---|---|---|---|
| Age (years) | 73.3 ± 6.3 | 69.7 ± 10.9 | 0.491 |
| Gender (Male/Female) | 22/8 | 45/1 |
|
| Obesity | 7 (23.3%) | 8 (17.4%) | 0.525 |
| Hypertension | 13 (43.3%) | 23 (50.0%) | 0.569 |
| DM | 11 (36.7%) | 16 (34.8%) | 0.867 |
| Cigarette smoking | 13 (43.3%) | 34 (73.9%) |
|
| Albumin (g/dL) | 3.7 (2.5–5.0) | 3.9 (2.8–4.6) | 0.658 |
| Total Bilirubin (mg/dL) | 0.5 (0.2–1.3) | 0.5 (0.2–0.9) | 0.834 |
| Platelet count (×104/mm3) | 20.8 (8.0–40.4) | 17.8 (6.7–51.6) | 0.100 |
| NLR | 2.12 (0.87–12.80) | 2.15 (0.79–7.43) | 0.461 |
| PT (%) | 93.0 (54.8–131.4) | 100.5 (63.4–131.4) | 0.714 |
| ICG R15 (%) | 11.4 (0.3–29.0) | 9.9 (1.6–31.5) | 0.124 |
| AFP (ng/mL) | 7.0 (1–48157) | 5.0 (1–7153) | 0.398 |
| DCP (mAU/mL) | 94.0 (14–85330) | 80.0 (11–15387) | 0.741 |
| Child-Pugh B/C | 3 (10.0%) | 3 (6.5%) | 0.583 |
| Multiple tumors | 10 (33.3%) | 12 (26.1%) | 0.496 |
| Tumor size (cm) | 5.0 (1.0–15.0) | 3.8 (1.2–17.0) | 0.229 |
| ≧10 cm | 6 (20.0%) | 8 (17.4%) | 0.774 |
| BCLC stage B/C | 9 (30.0%) | 9 (19.6%) | 0.296 |
| Beyond Milan criteria | 19 (63.3%) | 19 (41.3%) | 0.060 |
| Preoperative TACE | 15 (50.0%) | 27 (58.7%) | 0.456 |
NALP: non-alcoholic patients; ALP: alcoholic patients; DM: diabetes mellitus; NLR: neutrophil-to-lymphocyte ratio; PT: prothrombin time; ICG R15: indocyanine green retention rate at 15 minutes; AFP: serum α-fetoprotein; DCP: des-r-carboxyprothrombin; BCLC: Barcelona Clinic Liver Cancer; TACE: transcatheter arterial chemoembolization.
Intraoperative, pathological and postoperative factors in Group NBNC according to alcohol consumption.
| NALP ( | ALP ( |
| |
|---|---|---|---|
| ≧2 sentionectomy | 13 (43.3%) | 19 (41.3%) | 0.861 |
| Operative Time (min.) | 385 (173–983) | 340 (202–572) | 0.073 |
| Blood loss (g) | 1182 (200–36000) | 1280 (200–33478) | 0.663 |
| Curability R0 | 29 (96.7%) | 41 (89.1%) | 0.449 |
| Simple nodular type | 9 (30.0%) | 21 (45.7%) | 0.172 |
| Poorly differentiated | 2 (6.7%) | 4 (8.7%) | 0.748 |
| fc(+) | 18 (60.0%) | 26 (56.5%) | 0.764 |
| vp(+) | 12 (40.0%) | 16 (34.8%) | 0.645 |
| vv(+) | 2 (6.7%) | 5 (10.9%) | 0.536 |
| im(+) | 2 (6.7%) | 5 (10.9%) | 0.536 |
| Non-cancerous liver NL | 8 (26.7%) | 15 (32.6%) | 0.582 |
| CH | 12 (40.0%) | 17 (37.0% ) | 0.789 |
| LC | 9 (30.0% ) | 14 (30.4%) | 0.968 |
| Clavien-Dindo ≧ III | 7 (23.3%) | 5 (10.9%) | 0.145 |
| PHLF B/C | 9 (30.0%) | 9 (19.6%) | 0.296 |
| 90-day mortality | 1 (3.0%) | 5 (10.9%) | 0.234 |
| Intrahepatic recurrence | 11 (36.7%) | 14 (30.4%) | 0.572 |
| Extrahepatic recurrence | 3 (10.0%) | 4 (8.7%) | 0.848 |
NALP: non-alcoholic patients; ALP: alcoholic patients; fc: formation of capsule; vp: microscopic portal vein invasion; vv: microscopic hepatic vein invasion; im: intrahepatic metastasis; NL: normal liver; CH: chronic hepatitis; LC: liver cirrhosis; PHLF: posthepatectomy liver failure.
Histopathological examination based on Kleiner's classification.
| Item | Score/Code | NALP ( | ALP ( |
|
|---|---|---|---|---|
| Steatosis | 0 | 24 (80.0%) | 39 (84.8%) | 0.588 |
| 1 | 4 (13.3%) | 5 (10.9%) | 0.745 | |
| 2 | 1 (3.3%) | 2 (4.3%) | 0.824 | |
| 3 | 1 (3.3%) | 0 (0.0%) | 0.213 | |
| Lobular inflammation | 0 | 1 (3.3%) | 0 (0.0%) | 0.213 |
| 1 | 18 (60.0%) | 34 (73.9%) | 0.202 | |
| 2 | 8 (26.7%) | 11 (23.9%) | 0.786 | |
| 3 | 3 (10.0%) | 1 (2.2%) | 0.135 | |
| Ballooning | 0 | 20 (66.7%) | 35 (77.1%) | 0.369 |
| 1 | 8 (26.7%) | 7 (15.2%) | 0.220 | |
| 2 | 2 (6.7%) | 3 (6.5%) | 0.980 | |
| Fibrosis | 0 | 2 (6.7%) | 0 (0.0%) | 0.076 |
| 1 | 10 (33.3%) | 11 (23.9%) | 0.369 | |
| 2 | 3 (10.0%) | 11 (23.9%) | 0.126 | |
| 3 | 6 (20.0%) | 11 (23.9%) | 0.689 | |
| 4 | 9 (30.0%) | 13 (28.3%) | 0.870 | |
| NAS | 2 (0–5) | 2 (1–4) | 0.290 | |
| NAS with fibrosis | 4 (0–9) | 4 (2–8) | 0.996 |
NALP: nonalcoholic patients; ALP: alcoholic patients; NAS: nonalcoholic fatty liver disease (NAFLD) activity score, NAS of 5 was found in two patients (6.7%).
Figure 2Comparisons of overall survival and recurrence-free survival rates after hepatectomy between patients in group NBNC. (a) Overall survival. There were no significant differences in survival rates of two subgroups. (b) Recurrence-free survival. There were no significant differences in survival rates of two subgroups.
Multivariate analysis of factors contributing to overall survival and recurrence-free survival in group NBNC.
| Overall survival | Hazard ratio (95% CI) |
|
|---|---|---|
| Child-Pugh B/C | 19.667 (1.346–287.340) | 0.029 |
| im(+) | 31.064 (1.965–491.024) | 0.015 |
| Extrahepatic recurrence | 31.717 (1.261–797.764) | 0.036 |
im: intrahepatic metastasis.